SELLAS LIFE SCIENCES GROUP I (SLS)

Company Profile

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. The company is headquartered in New York City, New York and currently employs 17 full-time employees. The company went IPO on 2008-03-12. The firm is focused on the development of novel therapeutics for a range of cancer indications. The firm's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in 20 or more cancer types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers, and solid tumor indications. The firm is also developing GFH009, a small molecule, selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

Company Info

SELLAS LIFE SCIENCES GROUP I

7 Times Square, Suite 2503

New York City NEW YORK 10018

P: 16462005278

CEO: Angelos M. Stergiou

Employees: 17

Website: https://www.sellaslifesciences.com/